share_log

Johnson & Johnson | DEF 14A: Definitive information statements

Johnson & Johnson | DEF 14A: Definitive information statements

强生 | DEF 14A：股东委托书决议
SEC announcement ·  03/13 07:38
Moomoo AI 已提取核心信息
Johnson & Johnson (J&J) has announced the filing of its definitive proxy statement with the U.S. Securities and Exchange Commission (SEC) for its upcoming Annual Meeting of Shareholders scheduled for April 25, 2024. The proxy statement details the agenda for the meeting, including the election of 13 director nominees, an advisory vote on executive officer compensation, and the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal 2024. Additionally, two shareholder proposals are presented for consideration: one regarding gender-based compensation gaps and associated risks, and another on the impact of extended patent exclusivities on patient access. The Board of Directors has recommended voting against both shareholder proposals. The meeting will be held in a virtual format, and shareholders as of the record date, February 27, 2024, are eligible to vote. The proxy statement and annual report are available online, and shareholders are encouraged to vote in advance using the internet, phone, or mail.
Johnson & Johnson (J&J) has announced the filing of its definitive proxy statement with the U.S. Securities and Exchange Commission (SEC) for its upcoming Annual Meeting of Shareholders scheduled for April 25, 2024. The proxy statement details the agenda for the meeting, including the election of 13 director nominees, an advisory vote on executive officer compensation, and the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal 2024. Additionally, two shareholder proposals are presented for consideration: one regarding gender-based compensation gaps and associated risks, and another on the impact of extended patent exclusivities on patient access. The Board of Directors has recommended voting against both shareholder proposals. The meeting will be held in a virtual format, and shareholders as of the record date, February 27, 2024, are eligible to vote. The proxy statement and annual report are available online, and shareholders are encouraged to vote in advance using the internet, phone, or mail.
强生（J&J）宣布向美国证券交易委员会（SEC）提交定于2024年4月25日举行的年度股东大会的最终委托书。委托书详细说明了会议议程，包括选举13名董事候选人，就执行官薪酬进行咨询投票，以及批准普华永道会计师事务所为2024财年的独立注册会计师事务所。此外，还有两项股东提案供审议：一项涉及基于性别的薪酬差距和相关风险，另一项关于延长专利排他性对患者准入的影响。董事会建议对这两项股东提案投反对票。会议将以虚拟形式举行，截至记录日期，即2024年2月27日，股东有资格投票。委托书和年度报告可在线获取，鼓励股东提前使用互联网、电话或邮件进行投票。
强生（J&J）宣布向美国证券交易委员会（SEC）提交定于2024年4月25日举行的年度股东大会的最终委托书。委托书详细说明了会议议程，包括选举13名董事候选人，就执行官薪酬进行咨询投票，以及批准普华永道会计师事务所为2024财年的独立注册会计师事务所。此外，还有两项股东提案供审议：一项涉及基于性别的薪酬差距和相关风险，另一项关于延长专利排他性对患者准入的影响。董事会建议对这两项股东提案投反对票。会议将以虚拟形式举行，截至记录日期，即2024年2月27日，股东有资格投票。委托书和年度报告可在线获取，鼓励股东提前使用互联网、电话或邮件进行投票。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息